The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
April 4th 2024
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Dr. Farago on Eligibility Criteria for Frontline Immunotherapy in SCLC
August 7th 2019Anna F. Farago, MD, PhD, attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses patient eligibility criteria for frontline immunotherapy in small cell lung cancer (SCLC).
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Nears EU Approval in Nonsquamous NSCLC
July 29th 2019The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to the triplet regimen of atezolizumab (Tecentriq), carboplatin, and nab-paclitaxel (Abraxane) for the first-line treatment of patients with advanced, nonsquamous non–small cell lung cancer who do not have EGFR or ALK molecular aberrations.
Atezolizumab Plus Chemo Poised for EU Approval in Small Cell Lung Cancer
July 29th 2019The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of atezolizumab in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Dr. Peters on Creating Algorithms for Personalized Therapy in NSCLC
July 27th 2019Solange Peters, MD, PhD, of University Hospital Center Vaudois and Lausanne University in Switzerland, discusses the rapid advances in the lung cancer field and the importance of using biomarkers to create personalized immunotherapy treatments for patients.
Dr. Borghaei on CheckMate-227 Trial Updates in NSCLC
July 27th 2019Hossein Borghaei, DO, MS, chief of the Division of Thoracic Medical Oncology, professor of the Department of Hematology/Oncology, and co-director of the Immune Monitoring Facility at Fox Chase Cancer Center, discusses recent announcements from the CheckMate-227 trial in non–small cell lung cancer.
Immunotherapy Continues to Evolve Multimodal Stage III NSCLC Treatment
July 27th 2019Checkpoint inhibitors in the neoadjuvant setting, as consolidation post-chemoradiation, or in combination with concurrent chemoradiation, are all strategies actively being pursued in the locally advanced non–small cell lung cancer setting.
Frontline Nivolumab/Ipilimumab Improves OS in PD-L1+ NSCLC
July 25th 2019The combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) was superior in overall survival compared with chemotherapy for the first-line treatment of patients with non–small cell lung cancer whose tumors express PD-L1 ≥1%, meeting the co-primary endpoint of part 1a of the phase III CheckMate-227 trial.
Dr. Dumoulin on NVALT 12 Data in NSCLC
July 23rd 2019Daphne Dumoulin, MD, discusses the NVALT 12 study, a trial examining paclitaxel/carboplatin/bevacizumab inducing peripheral effector CD8 T-cell proliferation that could be prone to treatment in checkpoint inhibitors in patients with non–small cell lung cancer.
FDA Updates Durvalumab NSCLC Label to Include OS Data
July 22nd 2019The FDA has updated the label for durvalumab for patients with unresectable, stage III non–small cell lung cancer whose disease has not progressed following concurrent platinum-based chemoradiation to include overall survival data from the phase III PACIFIC trial.
Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC
July 19th 2019Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.
Dr. Gainor on Subgroup Analyses From the PACIFIC Trial in NSCLC
July 17th 2019Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).
Dr. Sequist on Implications of the IMpower150 Trial in Advanced Nonsquamous NSCLC
July 17th 2019Lecia V. Sequist, MD, MPH, the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital, discusses the implications of the phase III IMpower150 trial in advanced nonsquamous non–small cell lung cancer (NSCLC).